OSOleksandr Stakhovskyi

Oleksandr Stakhovskyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oleksandr Stakhovskyi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevated PSA in Patients with Combination of Chronic Prostatitis and Benign Prostatic Hyperplasia: Management Options and Improving Prostate Cancer Detection (Review article)

    by Valerii Zaitsev, Oleksandr Stakhovskyi, Vasyl Lypka, Валерій Зайцев, Василь Липка

    The relationship between chronic prostatitis (CP), which often coexists with benign prostatic hyperplasia (BPH), and elevated prostate-specific antigen (PSA) levels presents a clinical challenge, often complicating the decision-making process regarding prostate cancer (PCa) diagnosis. This overlap creates significant clinical challenges, as distinguishing between benign inflammatory conditions and malignancy is critical for determining the appropriate course of action. The treatment options for elevated PSA in the context of CP are not clearly defined in current guidelines. While most studies suggest that antibiotics are the most typical management strategy in such cases, the choice of antibiotic and optimal treatment duration remain unclear. Some research has explored the use of fluoroquinolones and other broad-spectrum antibiotics, but consensus on the most effective regimen is lacking. Additionally, there is limited evidence regarding the long-term outcomes of antibiotic therapy in these cases. Although most studies have shown that PSA levels decrease following antibiotic treatment, it remains uncertain whether this reduction improves the accuracy of PCa diagnosis. A drop in PSA may reflect the resolution of inflammation rather than the absence of cancer, posing a risk of overlooking malignancies. Another significant challenge is that inflammatory processes in the prostate can deteriorate and complicate histological analysis, further obscuring PCa diagnosis. Inflammation may alter tissue architecture, making it harder to detect malignant cells and increasing the risk of both false-positive and false-negative findings. This complicates the interpretation of prostate biopsies and may delay appropriate cancer treatment. Emerging research has started to focus on novel biomarkers, such as Prostate Health Index (PHI), 4Kscore, and urinary markers like PCA3 and TMPRSS2:ERG, which may offer additional diagnostic value beyond PSA alone. These markers have shown promise in differentiating CP from PCa, but their clinical utility requires further validation through large-scale studies. In conclusion, the relationship between CP, PSA levels, and PCa remains complex and poorly defined. Future research should aim to establish standardized treatment protocols for PSA elevation in patients with CP and BPH, clarify the role of antibiotics, and explore the integration of new biomarkers into routine clinical practice. This review highlights the importance of individualized diagnostic strategies and the integration of novel biomarkers to optimize patient management, reduce unnecessary biopsies, and improve clinical outcomes. Ongoing research remains crucial for refining these approaches and establishing evidence-based guidelines for the diagnosis and treatment of CP and PCa.

  • Open Access

    Modification of fast-track surgery during partial nephrectomy

    by O.A. Voylenko, M.V. Pikul, S.L. Semko, O.E. Stakhovskyi, B.O. Hrechko, A.V. Tymoshenko, D.O. Koshel, O.A. Kononenko, Iu.V. Vitruk, E.O. Stakhovskyi

    The present study aimed to assess the efficacy of the multimodal fast-track surgery (FTS) program supplemented with the exclusion of renal thermal ischemia, urinary tract drainage, and postoperative wound management in patients undergoing partial nephrectomy for localized T1 RCC. Methods. A total of 150 patients diagnosed with localized RCC in stage T1 N0 M0 were initially enrolled in this prospective randomized study, with 75 patients assigned to each study group. Patients undergoing perioperative management following the FTS program were randomly assigned to the main study group. The control group comprised patients receiving standard postoperative care. The study specifically involved patients with kidney neoplasms not exceeding 7 cm in the largest diameter based on computed tomography data. Tumor size, localization, and the volume of functioning parenchyma were considered in the assessment. Results. Among the patients included, 24 cases (16%) underwent radical nephrectomy due to technical difficulties arising from tumor spread to the kidney hilum, rendering them ineligible for further analysis. Consequently, the clinical analysis focused on 126 patients. Within the main group, 64 cases (50.8%) of RCC underwent randomization, and the multimodal FTS program was applied during partial nephrectomy. The control group comprised 62 patients (49.2%). The median postoperative bed day in the main group was 1.5 days less compared to the control group, with values of 3.2 [2; 4] days versus 5 [4; 7] days, respectively (p < 0.001). Intraoperative complications occurred in 5 cases (4.0%) involving blood loss exceeding 1 liter (4 cases in the main group and 1 case in the control group). Transfusion of blood components occurred only once when the hemoglobin level dropped below 70 g/l. In the early postoperative period, a total of 9 complications (7.1%) were observed with pyelonephritis lasting more than 3 days diagnosed in 4 cases (3.2%) and wound suppuration in 1 case (0.8%). Despite the absence of drainage in postoperative wounds within the main group, ultrasound examinations revealed small retroperitoneal hematomas (up to 100 ml) requiring drainage in 3% of cases. Conclusions. The multimodal FTS program for patients with localized RCC during partial nephrectomy, coupled with the exclusion of central thermal ischemia of the kidney, avoidance of retroperitoneal space drainage, and early patient activation, demonstrated a significant reduction in postoperative bed while maintaining a comparable level of perioperative complications.

  • Open Access

    Impact of neoadjuvant targeted therapy on perioperative complications in patients with localized reno-cellular cancer

    by O. A. Voylenko, O. E. Stakhovskyi, O. A. Kononenko, S. L. Semko, M. V. Pikul, Yu. V. Vitruk, E. O. Stakhovsky

    Objective. To study the efficacy of neoadjuvant targeted therapy in treatment of localized reno-cellular cancer and to determine its impact on the perioperative complications rate. Materials and methods. There are presented the results of randomized investigation, conducted in 152 patients with localized reno-cellular cancer. Into the main group 75 (49.3%) patients were included, to whom neoadjuvant targeted therapy and operative treatment were conducted, and into the control group - 77 (50.7%) patients, to whom operative treatment was performed only. The groups were randomized in accordance to the main clinical parameters. Efficacy of treatment was estimated in accordance to RECIST 1.1 scale, complications – in accordance to Clavien-Dindo classification. Results. Neoadjuvant targeted therapy did not influence the operation duration: (95 ± 19) min – while conduction of targeted therapy and (108 ± 53) min – without conduction of targeted therapy, and duration of postoperative treatment: (5.6 ± 1.9) and (5.2 ± 2.3) bed-days, accordingly. The intraoperative blood loss volume in renal resection of the patients’ main group in comparison with patients of a control group have constituted (407 ± 224) and (317 ± 210) ml accordingly (p=0.013). Neoadjuvant targeted therapy did not influence the perioperative complications rate, which have occurred in 7 (9.3%) patients of the main and in 8 (10.7%) patients of a control group, and their severity did not exceed 3 degrees in accordance to Clavien-Dindo classification. Conclusion. Neoadjuvant targeted therapy do not increase the operation duration, the perioperative complications rate and postoperative treatment time, but increases the blood loss volume while performance of renal resection (p=0.013).

  • Open Access

    Quality of life in patients, suffering localized reno-cellular cancer after operative treatment

    by O. A. Voylenko, O. A. Kononenko, S. L. Semko, M. V. Pikul, O. E. Stakhovskyi, Yu. V. Vitruk, E. O. Stakhovsky

    Objective. To rise the efficacy of treatment in patients, suffering localized reno-cellular cancer (LRCC), studying quality of life in patients and determination of optimal procedure of operative treatment. Materials and methods. Of 511 patients, suffering LRCC (T1-T2 N0M0), in whom quality of life was estimated in accordance to the SF-36 questionnaire, renal resection was performed in 422 (82.6%), nephrectomy - 89 (17.4%). The observation duration median have constituted 28.9 mo (from 3 to 131 mo). Results. A patient’s cognition of the oncological disease missing have raised the quality of life self-estimation, predominantly in accordance to indices of psychological component of health after nephrectomy and after renal resection. Comparing the quality of life between the patients’ groups, there was obtained a statistically significant advantage of renal resection over nephrectomy in accordance to five indices of quality of life, including: physical functioning - 75 [65; 85] points after nephrectomy and 80 [70; 90] points after renal resection (p < 0.005); general state of health - 65 [57; 72] and 70 [65; 80] (p < 0.001); vital activity - 65 [55; 70] and 70 [60; 75] (p < 0.005); psychological health - 76 [60; 80] and 80 [68; 88] (p < 0.005); the emotionally-role functioning - 66.7 [66.7; 100] and 100 [66,7; 100] (p < 0.05) points, accordingly. Conclusion. Renal resection has a statistically proven advantage over nephrectomy in accordance to patients’ quality of life, determined, basing on data from the SF-36 questionnaire, predominantly due to better psychological self estimation of the patient’s state of health (p < 0.01). Difference between the investigated groups in accordance to indices of pain intensity, social and physical-role functioning was not established.

  • Open Access

    Особливості морфологічних змін в оцінці ефективностінеоад’ювантної таргетної терапії у хворих з локалізованимнирково–клітинним раком

    by O. A. Voylenko, V. M. Nepomnyaschy, O. E. Stakhovskyi, Yu. V. Vitruk, O. A. Kononenko, M. V. Pikul, S. L. Semko, E. O. Stakhovsky

    Мета. Визначити особливості морфологічних змін під впливом неоад’ювантної таргетної терапії (ТТ), проведеної хворим з локалізованим нирково-клітинним раком (НКР). Матеріали і методи. Вивчено дані 58 пацієнтів з локалізованим НКР, яким проведено два блоки неоад’ювантної ТТ з визначенням об’єктивної відповіді на лікування, подальшим оперативним втручанням та патоморфологічним дослідженням. Результати. Середній показник регресії пухлини (М ± SD) після проведення ТТ становив (20,5 ± 14,3)% (95% довірчий інтервал- ДІ 16 - 24,3). Оцінка регресії пухлини за шкалою RECIST 1.1: стабілізацію відмітили у 44 (75,9%) хворих; часткову регресію- у 14 (24,1%). Повної регресії чи прогресії процесу не спостерігали у жодного хворого. Середній показник регресії за навності 2-го ступеня градації за Фурманом становив (22,6 ± 14,4)% (95% ДІ 18,3 - 26,9); 3-го ступеняг радації за Фурманом - (17,1 ± 11,7)% (95% ДІ 7,3 - 26,9); 4-го ступеня градації за Фурманом - (3,8 ± 2,9)% (95% ДІ 1 - 8,5); оцінка за методом ANOVA: η2=0,13; power=0,72; p < 0,05. Середня частка некрозу пухлини під дією ТТ достовірно вище у хворих з частковою регресією. Кореляційної залежності тяжкості судинних змін та частки життєздатної пухлинної тканини від ступеня регресії НКР не виявлено. Висновки. Під впливом неоад’ювантної ТТ у хворих з локалізованим НКР відбулася регресія пухлини в середньому на (20,5 ± 14,3)%. Низький показник регресії НКР у хворих з 4-м ступенем гістопатологічної градації ядер за Фурманом - (3,8 ± 2,9)%, який свідчить про низьку ефективність ТТ (оцінка за методом ANOVA: η2 = 0,13; power = 0,72; p < 0,05), можна використовувати як прогностичний маркер відповіді.

  • Open Access

    Хірургічне лікування місцево-розповсюджених та рецидивних солідних пухлин черевної порожнини та заочеревинного простору з нефректомією ex vivo ex situ та аутотрансплантацією нирки

    by O. V. Vasylyev, S. S. Sikachyov, O. O. Kvasivka, V. I. Kopetskyi, D. O. Cheverdyuk, V. I. Dorozhynskyi, Yu. V. Vitruk, O. E. Stakhovskyi, K. V. Kopchak

    Мета. Покращення результатів лікування хворих з місцево-розповсюдженими та рецидивними солідними пухлинами черевної порожнини та заочеревинного простору. Матеріали і методи. За період з червня 2015 по січень 2018 р. в Національному інституті раку виконали комбіновані оперативні втручання з нефректомією 28 хворим з приводу первинних місцево-розповсюджених та рецидивних солідних пухлин черевної порожнини та заочеревинного простору. Результати. У 5 із 28 пацієнтів виконали нефректомію ex vivo ex situ з аутотрансплантацією нирки, у 4 - успішно. Гостре ушкодження нирок спостерігали у 6 (26%) хворих, яким аутотрансплантації нирки не виконували. Після операції померли 2 (8,7%) хворих. У пацієнтів, яким нирка була збережена, не спостерігали гострого ушкодження нирок, ніхто з цих пацієнтів не помер. Висновки. З метою профілактики розвитку гострого ушкодження та хронічної хвороби нирок у майбутньому можливість виконання аутотрансплантації нирки у разі хірургічного лікування солідних пухлин черевної порожнини та заочеревинного простору, окрім первинного раку нирки, повинна бути розглянута щодо кожного хворого. Дану процедуру доцільно виконувати в спеціалізованих лікувальних закладах, де накопичено досвід в онковаскулярній хірургії.